A study in The American Journal of Managed Care found that longer stays in hospice were associated with longer survival and lower end-of-life costs for patients with metastatic melanoma, a particularly deadly and increasingly common form of cancer.
managed care, healthcare, cancer, melanoma, hospice, ipilimumab, vemurafenib, metastatic, survival rates, end-of-life, healthcare costs, Affordable Care Act, patient-centered, palliative care
Advertisement
Articles by managed care, healthcare, cancer, melanoma, hospice, ipilimumab, vemurafenib, metastatic, survival rates, end-of-life, healthcare costs, Affordable Care Act, patient-centered, palliative care
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues
2
Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?
3
Provider Trust, Social Media Use Can Shape Vaccine Myth Belief
4
MS Likely Unfolds Along a Continuum Years Before First Symptoms
5